Lab
Quest Diagnostics Massachusetts LLC
Quest Diagnostics Massachusetts LLC was paid $199.86M by Medicaid between Jan 2018 and Dec 2024, across 478 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 13% of everything it billed.
33Billing provider infoQUEST DIAGNOSTICS MASSACHUSETTS LLC
MARLBOROUGH, MA 01752
MARLBOROUGH, MA 01752
33aNPI1194062448assigned 01/07/2013
33bProvider typeClinical Medical Laboratory
28Total paid$199.86M
24GClaims17,471,892
24DCodes billed478
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Massachusetts
Rank by total paid#2 of 63
Median peer was paid$473K
This provider vs. median423×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,323,998 | $27.08M | |
| 2019 | 2,366,965 | $24.38M | |
| 2020 | 2,060,583 | $26.75M | |
| 2021 | 2,578,702 | $32.45M | |
| 2022 | 2,667,314 | $30.53M | |
| 2023 | 2,847,953 | $30.36M | |
| 2024incomplete | 2,626,377 | $28.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 13% | 364,457 | 341,701 | $25.54M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 11% | 588,668 | 369,775 | $21.23M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.9% | 616,440 | 430,388 | $17.84M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.3% | 462,969 | 447,060 | $8.57M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.3% | 467,507 | 452,416 | $8.53M |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2.3% | 87,520 | 85,760 | $4.61M |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 2.2% | 6,544 | 6,527 | $4.40M |
| 86480 | 1.8% | 90,705 | 90,231 | $3.69M | |
| 81513 | 1.8% | 69,030 | 67,405 | $3.54M | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.8% | 261,454 | 259,922 | $3.53M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.6% | 132,599 | 132,418 | $3.13M |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.5% | 141,190 | 140,861 | $3.10M |
466 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.5% | 257,262 | $2.91M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.3% | 134,936 | $2.67M |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 438,719 | $2.52M |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 1.2% | 6,290 | $2.46M |
| 86003 | 1.2% | 34,974 | $2.31M | |
| 80050 | General health panel | 1.1% | 191,679 | $2.28M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.1% | 17,544 | $2.26M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.1% | 102,108 | $2.21M |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.1% | 524,358 | $2.18M |
| 87522 | Neg quan hep c or qual rna | 1.1% | 65,554 | $2.18M |
| 80061 | Lipid panel | 1.0% | 756,066 | $2.01M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 711,137 | $2.00M |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 396,008 | $1.90M |
| 80053 | Comprehensive metabolic panel | <1% | 713,751 | $1.90M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 50,904 | $1.89M |
| 87799 | <1% | 48,763 | $1.84M | |
| 83013 | <1% | 32,022 | $1.60M | |
| 86803 | <1% | 211,957 | $1.58M | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 4,476 | $1.37M |
| 87536 | <1% | 31,504 | $1.35M | |
| 87902 | <1% | 10,394 | $1.29M | |
| 83655 | <1% | 153,172 | $1.27M | |
| 87088 | <1% | 307,975 | $1.13M | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 22,400 | $1.08M |
| 82728 | <1% | 177,583 | $1.02M | |
| 82607 | <1% | 173,925 | $939K | |
| 85027 | <1% | 330,523 | $909K | |
| ATP17 | <1% | 172,315 | $876K | |
| 88142 | <1% | 47,733 | $862K | |
| 87070 | <1% | 133,815 | $857K | |
| 80074 | <1% | 29,968 | $801K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 275,571 | $718K |
| 87340 | <1% | 124,986 | $683K | |
| 86780 | <1% | 71,280 | $670K | |
| 87512 | <1% | 20,044 | $628K | |
| 82746 | <1% | 115,988 | $628K | |
| 87481 | <1% | 22,845 | $603K | |
| 87186 | <1% | 136,292 | $602K | |
| 87081 | <1% | 115,929 | $602K | |
| ATP03 | <1% | 119,932 | $593K | |
| 84153 | <1% | 82,774 | $578K | |
| 84403 | <1% | 40,893 | $565K | |
| 84702 | <1% | 54,214 | $560K | |
| 84439 | <1% | 137,026 | $553K | |
| 86317 | <1% | 59,667 | $544K | |
| 81329 | <1% | 5,111 | $526K | |
| 83550 | <1% | 157,063 | $525K | |
| 87077 | <1% | 153,579 | $514K | |
| 81001 | <1% | 264,250 | $476K | |
| 80081 | <1% | 6,744 | $475K | |
| ATP14 | <1% | 180,990 | $447K | |
| 82043 | <1% | 158,917 | $446K | |
| 86592 | <1% | 162,380 | $443K | |
| 86235 | <1% | 12,192 | $429K | |
| 87650 | <1% | 23,315 | $427K | |
| 83540 | <1% | 165,497 | $410K | |
| 87631 | <1% | 4,150 | $408K | |
| 86704 | <1% | 53,554 | $407K | |
| 87510 | <1% | 23,077 | $385K | |
| 87660 | <1% | 23,046 | $381K | |
| 87480 | <1% | 23,101 | $380K | |
| 82670 | <1% | 26,286 | $363K | |
| 88141 | <1% | 21,786 | $360K | |
| 83970 | <1% | 32,761 | $357K | |
| 86787 | <1% | 44,613 | $352K | |
| 82570 | <1% | 179,085 | $352K | |
| 84146 | <1% | 38,723 | $348K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,084 | $344K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 7,386 | $340K |
| 86618 | <1% | 41,050 | $336K | |
| 82105 | <1% | 30,192 | $329K | |
| 82274 | <1% | 26,520 | $309K | |
| 86762 | <1% | 39,868 | $297K | |
| 88112 | <1% | 17,876 | $291K | |
| 83001 | <1% | 29,660 | $288K | |
| 87517 | <1% | 9,771 | $287K | |
| 86708 | <1% | 38,302 | $280K | |
| 88342 | <1% | 5,375 | $278K | |
| 86038 | <1% | 50,489 | $273K | |
| 86140 | <1% | 90,152 | $273K | |
| 82784 | <1% | 40,667 | $270K | |
| 83735 | <1% | 97,158 | $262K | |
| 82652 | <1% | 12,489 | $261K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,933 | $251K |
| 83516 | <1% | 29,798 | $247K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 14,519 | $244K |
| 83880 | <1% | 17,988 | $243K | |
| 86696 | <1% | 19,539 | $233K | |
| 82785 | <1% | 20,031 | $228K | |
| 83002 | <1% | 23,079 | $222K | |
| 86706 | <1% | 38,014 | $208K | |
| 80076 | <1% | 84,042 | $203K | |
| 86735 | <1% | 24,239 | $200K | |
| 86769 | <1% | 7,005 | $200K | |
| 85610 | <1% | 112,797 | $197K | |
| 84402 | <1% | 12,044 | $193K | |
| 86361 | <1% | 17,360 | $191K | |
| 80055 | <1% | 10,703 | $190K | |
| 86665 | <1% | 9,195 | $187K | |
| 81511 | <1% | 890 | $179K | |
| 84481 | <1% | 26,005 | $170K | |
| 86376 | <1% | 20,659 | $170K | |
| 86008 | <1% | 6,516 | $169K | |
| 88341 | <1% | 3,249 | $169K | |
| ATP11 | <1% | 34,542 | $169K | |
| 86765 | <1% | 24,592 | $166K | |
| ATP15 | <1% | 38,659 | $166K | |
| 84460 | <1% | 101,187 | $162K | |
| 86617 | <1% | 10,555 | $161K | |
| 82627 | <1% | 12,736 | $158K | |
| 86695 | <1% | 19,008 | $158K | |
| 85652 | <1% | 100,332 | $157K | |
| 87147 | <1% | 33,902 | $155K | |
| 86200 | <1% | 19,105 | $154K | |
| 87209 | <1% | 17,171 | $153K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 77,367 | $150K |
| 83020 | <1% | 15,676 | $150K | |
| 87901 | <1% | 1,239 | $149K | |
| ATP08 | <1% | 86,774 | $147K | |
| 82248 | <1% | 92,475 | $147K | |
| 88312 | <1% | 3,222 | $146K | |
| ATP18 | <1% | 28,245 | $143K | |
| 87338 | <1% | 13,606 | $134K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,292 | $131K |
| 84450 | <1% | 88,381 | $130K | |
| 86360 | <1% | 7,781 | $129K | |
| 87255 | <1% | 6,701 | $129K | |
| 87625 | <1% | 7,704 | $127K | |
| 83721 | <1% | 36,652 | $127K | |
| 82950 | <1% | 32,366 | $125K | |
| 86364 | <1% | 16,065 | $123K | |
| 86850 | <1% | 24,787 | $119K | |
| 86666 | <1% | 5,325 | $117K | |
| 83021 | <1% | 8,959 | $116K | |
| 84270 | <1% | 9,159 | $113K | |
| 82533 | <1% | 13,815 | $112K | |
| 80164 | <1% | 25,180 | $111K | |
| 86800 | <1% | 14,852 | $110K | |
| ATP04 | <1% | 19,550 | $110K | |
| 83690 | <1% | 32,063 | $109K | |
| 84436 | <1% | 37,110 | $106K | |
| 88304 | <1% | 4,409 | $96K | |
| 86160 | <1% | 8,610 | $95K | |
| 87469 | <1% | 3,740 | $95K | |
| 84144 | <1% | 7,742 | $94K | |
| 81596 | <1% | 3,086 | $94K | |
| 82150 | <1% | 23,438 | $92K | |
| 84703 | <1% | 15,968 | $92K | |
| 87427 | <1% | 12,146 | $91K | |
| 87900 | <1% | 1,239 | $90K | |
| 87468 | <1% | 3,731 | $89K | |
| 86753 | <1% | 9,221 | $89K | |
| 82565 | <1% | 70,809 | $88K | |
| 80197 | <1% | 23,550 | $87K | |
| 86664 | <1% | 8,318 | $84K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 820 | $82K |
| 86431 | <1% | 29,598 | $82K | |
| 87449 | <1% | 12,645 | $82K | |
| 84479 | <1% | 29,841 | $81K | |
| 84480 | <1% | 14,827 | $81K | |
| 86039 | <1% | 13,438 | $81K | |
| 87484 | <1% | 2,963 | $80K | |
| 86147 | <1% | 4,848 | $79K | |
| 83520 | <1% | 10,111 | $78K | |
| 82977 | <1% | 26,063 | $76K | |
| 87177 | <1% | 17,188 | $75K | |
| 82951 | <1% | 6,423 | $75K | |
| ATP10 | <1% | 18,471 | $73K | |
| 86225 | <1% | 11,592 | $73K | |
| 87329 | <1% | 9,963 | $73K | |
| 84445 | <1% | 2,697 | $72K | |
| 83525 | <1% | 12,114 | $72K | |
| 80178 | <1% | 23,400 | $71K | |
| 86901 | <1% | 28,042 | $70K | |
| 87497 | <1% | 4,148 | $70K | |
| 86900 | <1% | 28,060 | $70K | |
| 85018 | <1% | 61,996 | $69K | |
| 87529 | <1% | 2,286 | $68K | |
| 87045 | <1% | 13,247 | $68K | |
| 81401 | <1% | 424 | $67K | |
| 80159 | <1% | 17,371 | $65K | |
| 86141 | <1% | 9,778 | $64K | |
| 82550 | <1% | 34,288 | $64K | |
| 85014 | <1% | 57,987 | $64K | |
| 83718 | <1% | 20,096 | $63K | |
| 83090 | <1% | 6,805 | $63K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 749,480 | $62K |
| 83498 | <1% | 2,691 | $62K | |
| 87075 | <1% | 12,754 | $61K | |
| 86334 | <1% | 9,028 | $61K | |
| 84100 | <1% | 45,351 | $61K | |
| 85730 | <1% | 17,723 | $59K | |
| 82677 | <1% | 3,155 | $59K | |
| ATP07 | <1% | 26,301 | $58K | |
| 84550 | <1% | 42,797 | $57K | |
| 82024 | <1% | 3,613 | $57K | |
| 86146 | <1% | 2,961 | $57K | |
| ATP13 | <1% | 11,633 | $56K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,095 | $56K |
| 82947 | <1% | 35,660 | $56K | |
| 84425 | <1% | 6,969 | $54K | |
| 82465 | <1% | 26,554 | $52K | |
| 84154 | <1% | 9,563 | $51K | |
| 84165 | <1% | 15,084 | $50K | |
| 87324 | <1% | 8,052 | $48K | |
| ATP02 | <1% | 17,166 | $48K | |
| 86705 | <1% | 6,348 | $47K | |
| 83921 | <1% | 7,929 | $47K | |
| 86336 | <1% | 3,158 | $46K | |
| 87046 | <1% | 8,026 | $45K | |
| ATP05 | <1% | 7,983 | $44K | |
| 87563 | <1% | 1,566 | $44K | |
| 84681 | <1% | 4,796 | $42K | |
| 84156 | <1% | 28,985 | $42K | |
| 86709 | <1% | 5,652 | $42K | |
| 84134 | <1% | 7,847 | $41K | |
| 80069 | <1% | 20,558 | $40K | |
| 85379 | <1% | 5,637 | $40K | |
| 81015 | <1% | 24,967 | $39K | |
| 84520 | <1% | 44,051 | $38K | |
| 87205 | <1% | 18,133 | $37K | |
| 86021 | <1% | 4,621 | $37K | |
| 82088 | <1% | 1,997 | $37K | |
| 86255 | <1% | 7,155 | $37K | |
| 82542 | <1% | 2,413 | $37K | |
| 85004 | <1% | 23,084 | $36K | |
| 84484 | <1% | 4,864 | $36K | |
| 81025 | <1% | 6,929 | $35K | |
| ATP06 | <1% | 6,689 | $35K | |
| ATP09 | <1% | 11,180 | $34K | |
| 87040 | <1% | 4,300 | $34K | |
| 82747 | <1% | 5,614 | $33K | |
| 81508 | <1% | 392 | $32K | |
| 81003 | <1% | 25,057 | $32K | |
| 80051 | <1% | 21,435 | $31K | |
| 82330 | <1% | 6,519 | $31K | |
| ATP16 | <1% | 7,177 | $31K | |
| 82955 | <1% | 3,913 | $30K | |
| 87906 | <1% | 403 | $30K | |
| 82040 | <1% | 20,206 | $30K | |
| 82247 | <1% | 21,655 | $30K | |
| 83014 | <1% | 4,815 | $29K | |
| 82390 | <1% | 5,084 | $29K | |
| 82172 | <1% | 2,585 | $29K | |
| 82378 | <1% | 4,162 | $29K | |
| 80047 | <1% | 5,549 | $28K | |
| 84432 | <1% | 3,530 | $28K | |
| 87150 | <1% | 1,312 | $27K | |
| 84075 | <1% | 20,228 | $26K | |
| 86663 | <1% | 2,763 | $26K | |
| 86777 | <1% | 2,759 | $26K | |
| 86778 | <1% | 2,215 | $26K | |
| 85246 | <1% | 1,353 | $26K | |
| 86645 | <1% | 2,297 | $26K | |
| 84207 | <1% | 2,390 | $26K | |
| 85045 | <1% | 12,206 | $25K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 493 | $25K |
| 86308 | <1% | 5,855 | $24K | |
| 82787 | <1% | 2,641 | $24K | |
| 83010 | <1% | 3,771 | $24K | |
| 86258 | <1% | 2,595 | $24K | |
| 86304 | <1% | 2,077 | $24K | |
| 81243 | <1% | 500 | $24K | |
| 86341 | <1% | 1,480 | $23K | |
| 82103 | <1% | 3,604 | $23K | |
| 87350 | <1% | 3,127 | $23K | |
| 83615 | <1% | 11,595 | $23K | |
| 86812 | <1% | 1,246 | $22K | |
| 86481 | <1% | 359 | $22K | |
| 86747 | <1% | 1,128 | $22K | |
| 84155 | <1% | 16,838 | $22K | |
| 84244 | <1% | 2,102 | $21K | |
| 84305 | <1% | 1,989 | $21K | |
| 84630 | <1% | 3,183 | $21K | |
| 87493 | <1% | 2,994 | $21K | |
| 82310 | <1% | 16,621 | $20K | |
| 86593 | <1% | 9,631 | $20K | |
| 86870 | <1% | 839 | $19K | |
| 86644 | <1% | 2,161 | $19K | |
| 82952 | <1% | 5,844 | $19K | |
| 86359 | <1% | 1,928 | $19K | |
| ATP12 | <1% | 4,485 | $19K | |
| 85007 | <1% | 11,816 | $19K | |
| 85041 | <1% | 10,332 | $19K | |
| 80177 | <1% | 4,992 | $18K | |
| 87106 | <1% | 2,914 | $18K | |
| 83883 | <1% | 3,251 | $18K | |
| 83521 | <1% | 1,974 | $17K | |
| 82668 | <1% | 2,145 | $17K | |
| 87102 | <1% | 2,825 | $17K | |
| 85048 | <1% | 24,601 | $16K | |
| 85060 | <1% | 1,359 | $16K | |
| 84590 | <1% | 3,104 | $16K | |
| 80202 | <1% | 2,537 | $15K | |
| 84163 | <1% | 1,043 | $15K | |
| 87999 | <1% | 303 | $15K | |
| 80156 | <1% | 5,128 | $15K | |
| 86300 | <1% | 1,574 | $14K | |
| 80175 | <1% | 3,838 | $14K | |
| 83835 | <1% | 1,836 | $14K | |
| 87101 | <1% | 2,676 | $14K | |
| 82530 | <1% | 1,514 | $14K | |
| 86707 | <1% | 1,984 | $14K | |
| 84466 | <1% | 2,524 | $13K | |
| 80299 | <1% | 2,375 | $13K | |
| 81512 | <1% | 59 | $13K | |
| 86381 | <1% | 1,720 | $12K | |
| 80185 | <1% | 4,130 | $12K | |
| 82672 | <1% | 753 | $12K | |
| 85245 | <1% | 627 | $12K | |
| 84132 | <1% | 9,260 | $12K | |
| 84478 | <1% | 8,528 | $12K | |
| 85613 | <1% | 2,209 | $12K | |
| ATP19 | <1% | 2,922 | $11K | |
| 84482 | <1% | 1,086 | $11K | |
| 82140 | <1% | 1,853 | $11K | |
| 84166 | <1% | 2,145 | $11K | |
| 82985 | <1% | 3,215 | $11K | |
| 83704 | <1% | 721 | $10K | |
| 86162 | <1% | 964 | $10K | |
| 82525 | <1% | 1,392 | $10K | |
| 87140 | <1% | 1,909 | $10K | |
| 80165 | <1% | 1,793 | $10K | |
| 83698 | <1% | 336 | $10K | |
| 86335 | <1% | 1,229 | $10K | |
| 87076 | <1% | 1,917 | $9K | |
| 83519 | <1% | 1,762 | $9K | |
| 83993 | <1% | 2,149 | $9K | |
| 89055 | <1% | 3,636 | $9K | |
| 85240 | <1% | 567 | $8K | |
| 86702 | <1% | 1,739 | $8K | |
| 83695 | <1% | 1,282 | $8K | |
| 81241 | <1% | 276 | $8K | |
| 80158 | <1% | 1,064 | $8K | |
| 86060 | <1% | 1,441 | $8K | |
| 86301 | <1% | 823 | $7K | |
| 82164 | <1% | 1,109 | $7K | |
| 85660 | <1% | 1,616 | $7K | |
| 82107 | <1% | 198 | $7K | |
| 88307 | <1% | 35 | $7K | |
| 87254 | <1% | 317 | $7K | |
| 87280 | <1% | 609 | $7K | |
| 86036 | <1% | 1,544 | $7K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 8,345 | $7K |
| 86015 | <1% | 1,798 | $7K | |
| 84446 | <1% | 1,301 | $6K | |
| 87535 | <1% | 267 | $6K | |
| 80183 | <1% | 1,395 | $6K | |
| 86682 | <1% | 484 | $6K | |
| 83935 | <1% | 2,535 | $6K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 4,193 | $6K |
| 87328 | <1% | 742 | $6K | |
| 82085 | <1% | 1,360 | $6K | |
| 86337 | <1% | 528 | $6K | |
| 87220 | <1% | 2,088 | $6K | |
| 84300 | <1% | 3,050 | $6K | |
| 86701 | <1% | 1,734 | $6K | |
| 80162 | <1% | 1,513 | $6K | |
| 82166 | <1% | 155 | $5K | |
| 87634 | <1% | 47 | $5K | |
| 83930 | <1% | 2,074 | $5K | |
| 84295 | <1% | 4,929 | $5K | |
| 80184 | <1% | 1,910 | $5K | |
| 83876 | <1% | 148 | $5K | |
| 87206 | <1% | 1,553 | $5K | |
| 82553 | <1% | 771 | $4K | |
| 87478 | <1% | 242 | $4K | |
| 87276 | <1% | 383 | $4K | |
| 82653 | <1% | 407 | $4K | |
| 87275 | <1% | 384 | $4K | |
| 86355 | <1% | 349 | $4K | |
| 88185 | <1% | 12 | $4K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 12,041 | $4K |
| 82340 | <1% | 1,213 | $4K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 1,449 | $3K |
| 87581 | <1% | 111 | $3K | |
| 85306 | <1% | 338 | $3K | |
| 86886 | <1% | 651 | $3K | |
| 82610 | <1% | 504 | $3K | |
| 86357 | <1% | 312 | $3K | |
| 84182 | <1% | 41 | $3K | |
| 86148 | <1% | 215 | $3K | |
| 84080 | <1% | 884 | $3K | |
| 87207 | <1% | 817 | $3K | |
| 85049 | <1% | 1,329 | $2K | |
| 82384 | <1% | 198 | $2K | |
| 81256 | <1% | 99 | $2K | |
| 89051 | <1% | 772 | $2K | |
| 85303 | <1% | 284 | $2K | |
| 84140 | <1% | 140 | $2K | |
| 88313 | <1% | 54 | $2K | |
| 82435 | <1% | 2,991 | $2K | |
| 82397 | <1% | 225 | $2K | |
| 82374 | <1% | 2,809 | $2K | |
| 86885 | <1% | 373 | $2K | |
| 86774 | <1% | 254 | $2K | |
| 89060 | <1% | 543 | $2K | |
| 87107 | <1% | 212 | $2K | |
| 85247 | <1% | 78 | $2K | |
| 87185 | <1% | 453 | $2K | |
| 82232 | <1% | 249 | $1K | |
| 86231 | <1% | 224 | $1K | |
| 85300 | <1% | 191 | $1K | |
| 82705 | <1% | 652 | $1K | |
| 86001 | <1% | 72 | $1K | |
| 81240 | <1% | 59 | $1K | |
| 88262 | <1% | 12 | $1K | |
| 86382 | <1% | 40 | $1K | |
| 83630 | <1% | 82 | $1K | |
| 86256 | <1% | 215 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 22 | $1K |
| 80195 | <1% | 461 | $1K | |
| 88230 | <1% | 12 | $1K | |
| 82523 | <1% | 365 | $1K | |
| 80186 | <1% | 312 | $1K | |
| 87521 | Neg quan hep c or qual rna | <1% | 61 | $971.92 |
| 86611 | <1% | 42 | $920.38 | |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | <1% | 976 | $853.02 |
| 88302 | <1% | 34 | $837.08 | |
| 87272 | <1% | 102 | $819.45 | |
| 80201 | <1% | 220 | $802.88 | |
| 86628 | <1% | 24 | $800.07 | |
| 81257 | <1% | 12 | $797.81 | |
| 85651 | <1% | 261 | $752.54 | |
| 84378 | <1% | 193 | $735.13 | |
| 84133 | <1% | 325 | $700.49 | |
| 82552 | <1% | 104 | $687.75 | |
| 88189 | <1% | 12 | $684.42 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 3,271 | $682.09 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 85 | $651.79 |
| 87486 | <1% | 21 | $570.75 | |
| 88184 | <1% | 12 | $570.31 | |
| 82157 | <1% | 26 | $550.94 | |
| 80198 | <1% | 81 | $523.90 | |
| 83789 | <1% | 90 | $320.56 | |
| 82180 | <1% | 49 | $313.37 | |
| 86790 | <1% | 61 | $303.05 | |
| 84252 | <1% | 24 | $290.71 | |
| 83003 | <1% | 28 | $278.48 | |
| 85598 | <1% | 25 | $263.20 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 1,632 | $251.05 |
| ATP20 | <1% | 169 | $236.45 | |
| 80203 | <1% | 77 | $218.63 | |
| 86738 | <1% | 25 | $215.76 | |
| 86648 | <1% | 25 | $207.10 | |
| 86340 | <1% | 28 | $195.03 | |
| 80171 | <1% | 37 | $189.03 | |
| 99001 | <1% | 2,529 | $173.59 | |
| 82626 | <1% | 13 | $163.59 | |
| 80235 | <1% | 12 | $136.24 | |
| 86215 | <1% | 12 | $130.56 | |
| 86161 | <1% | 12 | $121.78 | |
| 87015 | <1% | 25 | $118.57 | |
| 85597 | <1% | 28 | $113.23 | |
| 86880 | <1% | 40 | $99.06 | |
| 84238 | <1% | 26 | $96.91 | |
| 82104 | <1% | 26 | $88.73 | |
| 84560 | <1% | 26 | $71.93 | |
| G0307 | Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) | <1% | 1,169 | $59.11 |
| 82656 | <1% | 25 | $57.76 | |
| G0306 | Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count | <1% | 943 | $55.81 |
| 82365 | <1% | 12 | $55.30 | |
| 86316 | <1% | 13 | $55.05 | |
| 80173 | <1% | 12 | $21.39 | |
| 36416 | <1% | 848 | $0.59 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | 0% | 276 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBETZ, DAVID (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Quest Diagnostics Massachusetts LLC | East Boston, MA | $217K |
| Quest Diagnostics Massachusetts LLC | East Boston, MA | $32K |
| Quest Diagnostics Massachusetts LLC | Brockton, MA | $22K |
| Quest Diagnostics Massachusetts LLC | Stoughton, MA | $6K |
| Quest Diagnostics Massachusetts LLC | Hyannis, MA | $3K |
| Quest Diagnostics Massachusetts LLC | Worcester, MA | $959.61 |
| Quest Diagnostics Massachusetts LLC | Worcester, MA | $16.24 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.